|Awarded On||May 18, 2022|
|Title||Recruitment of Established Investigators|
|Award Mechanism||Recruitment of Established Investigators|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Pavan Reddy|
|Cancer Sites||Leukemia, Lymphoma, Myeloma|
|Summary of Goals and Objectives||
The therapeutic potential of T-cell immunotherapy is limited by major immunotoxicities such as graft-versus-host disease (GVHD), immune checkpoint blocker (ICB) colitis and the loss of persistence, and exhaustion of transferred T cells. This proposal aims to address these problems. It blends hypothesis-driven studies that are informed by unbiased discovery-based explorations. Most advances in the field are focused on the sensor and effector arms of the problem, namely the immune cells. Herein we will take a distinct approach; focus on both immune target cells and on effector T cells. Thus, the goals of the proposal are two themes that tackle the two ends of the immunotherapy: the targets and...